Plain-English translation of NCT05288205 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing whether two medications called and , given together, can safely treat advanced cancers (including lung, colorectal, and pancreatic cancers) that have a specific genetic mutation called KRAS p.G12C. The trial has two parts: first, doctors will test different doses to find the safest and most effective combination, and then they will study how well this combination works in larger groups of patients with specific cancer types.
Many patients with cancers that have the KRAS p.G12C mutation don't have good treatment options or don't respond well to standard therapies. This trial is exploring whether combining these two newer medications could offer a better treatment choice for people in that situation.
You likely qualify if…
You likely don't qualify if…
You would take both medications by mouth, starting at a carefully monitored dose. In the first phase of the trial, your dose may be adjusted to find the safest level that works best. You'll have regular visits with the study team for blood tests, imaging scans to measure your tumors, and checkups to monitor how you're responding and whether you're experiencing any side effects. The study will continue as long as the treatment is working and you're tolerating it well.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China